As IL-33 appears to play a role in inflammatory responses of the lung following RV exposure, newer biologic therapies targeting IL-33 signaling, such as astegolimab and itepekimab, may also be effective in preventing RV-induced asthma exacerbations and subsequent airway remodeling [180, 185, 186]. Here, IL33 is linked to asthma.